

Ahmed F Abdel-Magid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1167177/publications.pdf>

Version: 2024-02-01

25
papers

82
citations

1937685

4
h-index

1720034

7
g-index

25
all docs

25
docs citations

25
times ranked

111
citing authors

#	ARTICLE	IF	CITATIONS
1	The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases. ACS Medicinal Chemistry Letters, 2022, 13, 19-21.	2.8	7
2	Therapeutic Potential of Monoacylglycerol Lipase (MGL) Inhibitors as Treatment for Pain, Depression, Cancers, and Eye Conditions. ACS Medicinal Chemistry Letters, 2022, 13, 22-24.	2.8	1
3	Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy. ACS Medicinal Chemistry Letters, 2021, 12, 182-184.	2.8	5
4	Myeloid Cell Leukemia-1 Inhibitors as Emerging Cancer Treatment. ACS Medicinal Chemistry Letters, 2021, 12, 334-336.	2.8	3
5	Reactivation of the Guardian of the Genome P53: A Promising Strategy for Treatment of Cancer. ACS Medicinal Chemistry Letters, 2021, 12, 331-333.	2.8	4
6	The Potential of c-KIT Kinase inhibitors in Cancer Treatment. ACS Medicinal Chemistry Letters, 2021, 12, 1191-1192.	2.8	4
7	Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists May Provide a Superior Treatment for Pain and Migraine. ACS Medicinal Chemistry Letters, 2021, 12, 1193-1195.	2.8	3
8	Cannabinoid Receptor Agonists for the Potential Treatment of Pain, Neurological Disorders, Fibrotic Diseases, Obesity, and Many More. ACS Medicinal Chemistry Letters, 2021, 12, 1188-1190.	2.8	3
9	Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases. ACS Medicinal Chemistry Letters, 2021, 12, 1889-1891.	2.8	3
10	Adenosine Receptor Antagonists as Potential Cancer Therapy. ACS Medicinal Chemistry Letters, 2021, 12, 1892-1893.	2.8	0
11	Therapeutic Potential of Autotaxin Inhibitors in Treatment of Interstitial Lung Diseases. ACS Medicinal Chemistry Letters, 2020, 11, 2075-2076.	2.8	0
12	Use of Dihydroorotate Dehydrogenase Inhibitors for Treatment of Autoimmune Diseases and Cancer. ACS Medicinal Chemistry Letters, 2020, 11, 2072-2074.	2.8	5
13	Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer. ACS Medicinal Chemistry Letters, 2020, 11, 1079-1080.	2.8	1
14	Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta. ACS Medicinal Chemistry Letters, 2020, 11, 1083-1085.	2.8	4
15	Potential Cancer Treatment by Agonists of the Stimulator of Interferon Genes. ACS Medicinal Chemistry Letters, 2020, 11, 1081-1082.	2.8	1
16	Lysophosphatidic Acid Receptor 1 Antagonists for the Treatment of Fibrosis. ACS Medicinal Chemistry Letters, 2019, 10, 1378-1379.	2.8	2
17	Second-Generation FGFR Inhibitors for the Treatment of Cancers Harboring Mutated FGFRs. ACS Medicinal Chemistry Letters, 2019, 10, 1374-1375.	2.8	1
18	Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment. ACS Medicinal Chemistry Letters, 2019, 10, 1376-1377.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Rapalogs Potential as Practical Alternatives to Rapamycin. ACS Medicinal Chemistry Letters, 2019, 10, 843-845.	2.8	11
20	Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders with GPR119 Agonists. ACS Medicinal Chemistry Letters, 2019, 10, 14-15.	2.8	4
21	ASK1: A Therapeutic Target for the Treatment of Multiple Diseases. ACS Medicinal Chemistry Letters, 2019, 10, 12-13.	2.8	6
22	Therapeutic Potential of FXR Agonists in the Treatment of Multiple Diseases. ACS Medicinal Chemistry Letters, 2018, 9, 294-295.	2.8	0
23	Potential of PDE10A Inhibitors as Treatment for Schizophrenia and Other Neurological Disorders. ACS Medicinal Chemistry Letters, 2018, 9, 866-867.	2.8	3
24	Potential Treatment of Acute Leukemia with Inhibitors of Menin/MLL Interaction. ACS Medicinal Chemistry Letters, 2018, 9, 868-869.	2.8	3
25	GPR40 Receptor Agonists for the Treatment of Type 2 Diabetes and Related Diseases. ACS Medicinal Chemistry Letters, 2018, 9, 870-871.	2.8	8